Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» glecaprevir/pibrentasvir
glecaprevir/pibrentasvir
AbbVie, Enanta post stellar hep C PhIII data, but no one is cheering
Endpoints
Thu, 04/20/17 - 08:52 pm
AbbVie
Enanta
hepatitis C
glecaprevir/pibrentasvir
AbbVie's Hepatitis C Treatment Under Priority Review in Japan
Yahoo/GuruFocus
Wed, 03/15/17 - 09:47 pm
AbbVie
hepatitis C
Japan
glecaprevir/pibrentasvir
U.S. FDA Grants Priority Review to AbbVie for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
Yahoo
Thu, 02/2/17 - 09:22 am
FDA
AbbVie
glecaprevir/pibrentasvir
G/P
hepatitis C
AbbVie Files for Approval of Hepatitis C Treatment in the US
Yahoo/GuruFocus
Tue, 12/20/16 - 12:20 pm
AbbVie
hepatitis C
glecaprevir/pibrentasvir
After The Deluge, Hep C Players Look For Opportunity
Seeking Alpha
Thu, 11/17/16 - 09:57 am
hepatitis C
Gilead Sciences
AbbVie
Epclusa
glecaprevir/pibrentasvir
sofosbuvir/velpatasvir
AbbVie reports positive 8-week data in HCV
BioPharma Dive
Mon, 11/14/16 - 12:00 pm
AbbVie
hepatitis C
glecaprevir/pibrentasvir
AbbVie Receives FDA Ranking for Hepatitis C Therapy
Yahoo/GuruFocus
Mon, 10/3/16 - 09:51 pm
AbbVie
FDA
hepatitis C
glecaprevir/pibrentasvir